Market capitalization | $1.01b |
Enterprise Value | $730.05m |
P/E (TTM) P/E ratio | negative |
EV/FCF (TTM) EV/FCF | negative |
EV/Sales (TTM) EV/Sales | 11.74 |
P/S ratio (TTM) P/S ratio | 16.19 |
P/B ratio (TTM) P/B ratio | 2.77 |
Revenue growth (TTM) Revenue growth | -86.52% |
Revenue (TTM) Revenue | $62.20m |
As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.
8 Analysts have issued a Zymeworks Inc. forecast:
8 Analysts have issued a Zymeworks Inc. forecast:
Sep '24 |
+/-
%
|
||
Revenue | 62 62 |
87%
87%
|
|
Gross Profit | 51 51 |
88%
88%
|
|
EBITDA | -110 -110 |
150%
150%
|
EBIT (Operating Income) EBIT | -121 -121 |
159%
159%
|
Net Profit | -114 -114 |
155%
155%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Zymeworks, Inc. is a clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of biotherapeutics. Its product, ZW25 and ZW49 are a bispecific antibody that cans two non-overlapping epitopes. The company was founded by Anthony Fejes, J. Haig deB Farris, Nick Bedford, Ali Tehrani and Andrew S. Wright on September 8, 2003 and is headquartered in Vancouver, Canada.
Head office | Canada |
CEO | Ken Galbraith |
Employees | 277 |
Founded | 2003 |
Website | www.zymeworks.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.